Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 643
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT04379193 Physical Therapy and Neuroactive Steroids Therapy Does Not Modulate Ser… |
Physical Therapy and Neuroactive … | SEP | NA | COMPLETED | En attente / non publié | Charles University, Czech Republic | Non communiqué | 2015-05-20 → 2019-09-01 | Ouvrir |
| NCT01804660 CONTROL — Longitudinal Therapeutically Non-interventional Study of MSRV… |
CONTROL — Longitudinal Therapeuti… | SEP | À vérifier | COMPLETED | En attente / non publié | GeNeuro Innovation SAS | France · Etablissement Français du Sang Rhône Alpes -… | 2012-10 → 2013-12 | Ouvrir |
| NCT02782858 CHANGE-MS — Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 f… |
GNbAC1 | SEP | Phase 2 | COMPLETED | En attente / non publié | GeNeuro Innovation SAS | Bulgaria, Croatia, Czechia, Estonia, Germany, Hungary… | 2016-04 → 2017-12 | Ouvrir |
| NCT04838015 SEP-RR — Retrospective Study on Registry Data to Evaluate the Impact of… |
SEP-RR — Retrospective Study on R… | SEP | À vérifier | UNKNOWN | En attente / non publié | University Hospital, Strasbourg, … | France · Hautepierre Clinical Investigation Center - … | 2020-11-13 → 2021-11-13 | Ouvrir |
| NCT03873389 Ocrelizumab Effects on the Metabolome in MS |
Ocrelizumab | SEP | À vérifier | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States · Johns Hopkins University, Baltimore, … | 2019-06-12 → 2023-12-05 | Ouvrir |
| NCT05269888 CoVaR-MS — Covid-19 Vaccine Immune Response in Multiple Sclerosis |
CoVaR-MS — Covid-19 Vaccine Immun… | SEP | À vérifier | ACTIVE_NOT_RECRUITING | En attente / non publié | University Hospitals of North Mid… | United Kingdom · University Hospitals of North Midlan… | 2022-02-16 → 2025-12-30 | Ouvrir |
| NCT07149662 Immune System Effects in Children Born to Women With Multiple Sclerosis… |
monoclonal CD-20 antibodies | SEP | À vérifier | NOT_YET_RECRUITING | En attente / non publié | Region Stockholm | Sweden · Academic specialist center, Center for Neuro… | 2026-02 → 2028-03 | Ouvrir |
| NCT00912860 Immunogenicity and Safety Study of Serum-Free Avonex |
Interferon beta-1a | SEP | Phase 2 | COMPLETED | En attente / non publié | German University in Cairo | Non communiqué | 2003-01 → 2005-01 | Ouvrir |
| NCT03603691 Study to Evaluate the Reliability and Validity of the Modified Manual M… |
Study to Evaluate the Reliability… | SEP | NA | COMPLETED | En attente / non publié | Nanco van der Maas | Switzerland · Felix Platter Hospital, Basel, Switzerl… | 2018-08-01 → 2019-01-29 | Ouvrir |
| NCT05423769 Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in … |
Fingolimod | SEP | À vérifier | COMPLETED | En attente / non publié | Bristol-Myers Squibb | Egypt · Faculty of medicine Ain shams Research Instit… | 2022-01-19 → 2023-11-30 | Ouvrir |
| NCT04681586 Bright Light Therapy as Possible Treatment Option for MS-Fatigue |
bright light therapy | SEP | NA | UNKNOWN | En attente / non publié | Medical University of Vienna | Austria · Medical University of Vienna, Vienna, Austr… | 2019-12-01 → 2022-01 | Ouvrir |
| NCT02587195 TERICIS — A Study to Evaluate the Safety of Long Term Treatment With Te… |
Teriflunomide | SEP | Phase 3 | COMPLETED | En attente / non publié | Hoffmann-La Roche | France · CHU de Besançon, Besançon, France | CHU de L… | 2015-12-18 → 2021-08-31 | Ouvrir |
| NCT05127031 Validity and Reliability of VO2-max Measurements in Persons With Parkin… |
Validity and Reliability of VO2-m… | Parkinson | À vérifier | COMPLETED | En attente / non publié | University of Aarhus | Denmark · Sport Science, Department of Public Health,… | 2021-10-01 → 2022-06-01 | Ouvrir |
| NCT01804647 LOMBARD — Longitudinal Therapeutically Non-interventional Study of MSRV… |
LOMBARD — Longitudinal Therapeuti… | SEP | À vérifier | COMPLETED | En attente / non publié | GeNeuro Innovation SAS | France, Spain, Switzerland · Centre Hospitalier Unive… | 2012-11 → 2015-02 | Ouvrir |
| NCT04480307 ProTEct-MS — Clinical Trial Assessing Temelimab Following Rituximab Tre… |
Temelimab 18 mg/kg | SEP | Phase 2 | COMPLETED | En attente / non publié | GeNeuro Innovation SAS | Sweden · Center for Neurology, Academic Specialist Ce… | 2020-06-17 → 2022-01-24 | Ouvrir |
| NCT05054140 CALLIPER — Study to Evaluate Efficacy, Safety, and Tolerability of IMU-… |
IMU-838 | SEP | Phase 2 | UNKNOWN | En attente / non publié | Immunic AG | United States, Bulgaria, Canada, Czechia, Germany, Mo… | 2021-09-30 → 2025-01-07 | Ouvrir |
| NCT03239860 ANGEL-MS — Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in… |
GNbAC1 Monoclonal Antibody | SEP | Phase 2 | TERMINATED | En attente / non publié | GeNeuro SA | Bulgaria, Croatia, Czechia, Estonia, Germany, Hungary… | 2017-06-06 → 2018-11-14 | Ouvrir |
| NCT03179423 RAINBOW-T1D — Clinical Trial Assessing the GNbAC1 in Patients With Onse… |
GNbAC1 | SEP | Phase 2 | COMPLETED | En attente / non publié | GeNeuro Innovation SAS | Australia · AIM Centre, Merewether, Australia | Barwo… | 2017-06-14 → 2019-05-07 | Ouvrir |
| NCT07161258 FENerations1 — A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety a… |
Fenebrutinib | SEP | Phase 2 | RECRUITING | En attente / non publié | Hoffmann-La Roche | Argentina, Brazil, Mexico, Poland, Portugal, Spain, U… | 2025-10-06 → 2029-02-13 | Ouvrir |
| NCT04586010 FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib … |
Fenebrutinib | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Argentina, China, Dominican Republic, … | 2021-03-17 → 2027-11-30 | Ouvrir |
| NCT04586023 FENhance 2 — Study to Evaluate the Efficacy and Safety of Fenebrutinib … |
Fenebrutinib | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Austria, Brazil, Bulgaria, Canada, Den… | 2021-03-24 → 2027-07-09 | Ouvrir |
| NCT06890923 TILS-022 — Nasal Foralumab in Patients With Non-Active Secondary Progre… |
Foralumab TZLS-401 100 µg | SEP | Phase 2 | RECRUITING | En attente / non publié | Tiziana Life Sciences LTD | United States · Brigham and Women's Hospital, Boston,… | 2025-03-04 → 2026-08-30 | Ouvrir |
| NCT03993171 REPAIR-MS — 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaire… |
gold nanocrystals | SEP | Phase 2 | COMPLETED | En attente / non publié | Clene Nanomedicine | United States · University of Texas Southwestern, Dal… | 2019-12-19 → 2025-07-31 | Ouvrir |
| NCT03536559 VISIONARY-MS — Nanocrystalline Gold to Treat Remyelination Failure in C… |
CNM-Au8 | SEP | Phase 2 | TERMINATED | En attente / non publié | Clene Nanomedicine | United States, Australia, Canada · Alfred Health, Mel… | 2018-11-23 → 2022-07-12 | Ouvrir |
| NCT06083753 VISTA — Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjec… |
PIPE-307 Dose A | SEP | Phase 2 | COMPLETED | En attente / non publié | Janssen Research & Development, L… | United States · Alta Bates Summit Medical Center, Ber… | 2023-11-06 → 2025-08-04 | Ouvrir |